Product Description
Aspartic acid is a nonessential amino acid. Amino acids are building blocks of proteins. (Sourced from: https://medlineplus.gov/ency/article/002234.htm)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Dominican Republic | Ecuador | Egypt | Estonia | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Korea | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder with Hyperactivity
Known Adverse Events: Attention Deficit Disorder with Hyperactivity | Insomnia | Tachycardia | Abdominal Pain | Dizziness | Pain Unspecified | Anorexia | Weight Loss
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Romania, Ukraine
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Chronic Lymphoid Leukemia|Heart Transplant
Phase 1: Attention Deficit Disorder with Hyperactivity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VV022-02 | P2 |
Active, not recruiting |
Chronic Lymphoid Leukemia |
2026-07-31 |
|
| CL-N-HTX-Paed | P2 |
Not yet recruiting |
Heart Transplant |
2025-06-30 |
|
| DEADA-07-23 | P1 |
Not yet recruiting |
Attention Deficit Disorder with Hyperactivity |
2024-05-06 |